10549502 - GAU: 1654

					DEC 13	עע ניייט	SHE	- 1	OF		
Form PTO 1449		U.S. DEPARTMENT	OF COMMERCE	ATTY DOCKET NO.	TTY DOCKET NO.			SERIAL NO.			
(Modified)		PATENT AND TRAD	EMARK OFFICE	277165USOPCT			10/549,502				
				APPLICANT							
LIST OF	REFE	RENCES CITED BY API	PLICANT	Youcef FEZOUI, et	al.						
				FILING DATE			GROUP				
				September 14, 2005							
				U.S. PATENT DOCUMEN					-		
EXAMINER		DOCUMENT	Ι		NAME CLASS			FIL	ING DATE		
INITIAL		NUMBER 2002/0119926	DATE 08/29/02	NAME CLA FRASER			CLASS IF APPROPRIATE				
	AA										
	AB	6 610 824	08/26/03 FO	GAETA et al. REIGN PATENT DOCUM	ENTS		1				
DOCUMENT DATE COUNTRY TRANSLATION											
		NUMBER	DATE	COUNTRY			YES NO				
	AC	0 885 904	12/23/98				NO NO		-1		
	AD	96/39834	12/19/96	wo				_	NO	\neg	
	AE	1 162 207	12/12/01	EP					NO	_	
			05/17/01	wo					NO	-	
	AF	ı	•			_		1	NO	i	
				Including Author, Title, D							
	AG	MORIARTY et al. "Effects of Sequential Proline Substitutions on Amyloid Formation by Human Amylin", Biochemistry, vol. 38, pages 1811-1818 1999									
	АН	WESTERMARK et al. "Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation", Proc. Natl. Acad. Sci., vol. 87, pages 5036-5040 1990									
	AI	Tosu SOTO et al. "Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy", Nature Medicine, vol. 4, no. 7, pages 822-826									
	AJ	ANGUIANO et al. *Protofibrillar Islet Amyloid Polypeplide Permeabilizes Synthetic Vesicles by a Pore-like Mechanism that May Be Relevant to Type II Diabetes*, Blochemistry, vol. 41, pages 11338-11343 2002									
	AK	CARRELL et al. "Conformational Disease", The Lancet, vol. 350, pages 134-138 1997									
	AL	COOPER et al. "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients", Proc. Natl. Acad. Sci., vol. 84, pages 8628-8632 1987									
	AM	1987 DOBSON. "Protein misfolding, evolution and disease", TIBS, vol. 24, pages 329-332 1999									
	AN	FEZOUI et al. "An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments", Amyloid: Int. J. Exp. Clin. Invest., vol. 7, pages 166-178 2000									
	AO	GLENNER et al. "Amyloid Fibrils Formed from a Segment of the Pancreatic Islet Amyloid Protein", Biochemical and Biophysical Research Communications, vol. 155, no. 2, pages 608-614 1988									
	AP	HOEPPENER et al. "Islet Amyloid and Type 2 Diabetes Mellitus", Mechanisms of Disease, vol. 343, no. 6, pages 411-419 2000									
	AQ	KLUNK et al. "Quantifying Arryloid by Congo Red Spectral Shift Assay", Methods in Enzymology, vol. 309, pages 285-305 1999									
	AR	LORENZO et al. "Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus", Nature, vol. 368, pages 756-760 1994									
	AS		and biology of	amylin", Tips, vol. 14, pages 113-118 Additional References sheet(s) attached							
Examiner						Date Co	nsidered				
*Examiner: In conformance	itial if r	eference is considered, ot considered. Include co	whether or no	t citation is in conformance with next communication	with MPEP 60 to applicant.	9; Draw li	ne through	citation i	f not in		

SHEET 2 OF 2 SERIAL NO ATTY DOCKET NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Form PTO 1449 277165US0PCT 10/549.502 APPLICANT LIST OF REFERENCES CITED BY APPLICANT Youcef FEZOUI, et al. GROUP FILING DATE September 14, 2005 OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) SOTO, "Protein misfolding and disease; protein refolding and therapy", FEBS Letters, vol. 498, pages 204-207 AT 2001 LEVINE, "Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution", Protein Science, vol. 2, pages 404-410 TRIGUERO et al. "Capillary Depletion Method for Quantification of Blood-Brain Barrier Transport of Circulating Peptides and Plasma Proteins", Journal of Neurochemistry, vol. 54, pages 1882-1888 1990 AW ΑZ AAB AAC AAD AAE AAF AAG AAH AAI AAJ 02/06/2008 /Satyanarayan Gudibande/ Date Considered Examiner Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.